D. Fenton

M. Winget, C. Butts, K. King, 2013, International journal for quality in health care : journal of the International Society for Quality in Health Care.

A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer

Hua Liu, Balazs Halmos, Thomas J Lynch, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.

Sunita Ghosh, M. Sawyer, M. Smylie, 2015, Clinical lung cancer.

Feasibility and preliminary efficacy of progressive resistance exercise training in lung cancer survivors.

K. Courneya, L. Mccargar, G. Bell, 2012, Lung cancer.

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.

L. Seymour, K. Ding, F. Shepherd, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

A. Bezjak, L. Seymour, F. Shepherd, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study.

C. Lohrisch, S. Chia, T. Shenkier, 2021, Clinical breast cancer.

Phase I dose escalation trial of hypofractionated limited-field external beam thoracic radiotherapy for limited-stage small cell carcinoma of the lung.

M. Smylie, W. Roa, J. Hanson, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.

A. T. Freeman, M. Lesperance, D. Fenton, 2019, Current oncology.

Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC)

T. Lynch, B. Halmos, O. Eton, 2007 .

Detection of circulating plasma tumour mutations in early stage triple negative breast cancer as an adjunct to pathological complete response assessment.

S. Aparicio, C. Lohrisch, C. Bates, 2023, medRxiv.

Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer.

M. Winget, C. Butts, K. King, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.

P. Neven, D. Yee, K. Blackwell, 2011 .

Feasibility and preliminary efficacy of progressive resistance exercise training in lung cancer survivors.

K. Courneya, L. Mccargar, G. Bell, 2012, Lung cancer.

Timeliness of cancer care from diagnosis to treatment: a comparison between patients with breast, colon, rectal or lung cancer.

M. Winget, C. Butts, K. King, 2013, International journal for quality in health care : journal of the International Society for Quality in Health Care.